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Advances in defining mechanisms of cortical devel-
opment have been paralleled in recent years by an
intense interest in translating these findings into
greater insight of both childhood- and adult-onset
cognitive and mental health disorders of develop-
mental etiology. Successful integration of basic and
clinical findings have been applied to monogenic dis-
orders. The greater challenge lies in studying cortical
development in the context of gene × environment in-
teractions, which underlie the pathogenesis of the
most common neurodevelopmental disorders. This
can occur through an improved delineation of patho-
physiological characteristics unique to specific com-
plex disorders and the application of this information
to the refinement of the most relevant model systems.
Translational research has taken center stage in the ef-
forts of many basic neuroscientists attempting to place
individual biological findings in the context of brain dis-
orders and diseases. In particular, the world of develop-
mental neurobiology has been turned on its head as
more and more recent findings indicate that perturba-
tions of fundamental developmental processes may re-
late not only to disorders that are expressed by chil-
dren, but also to postadolescent and adult disorders
that have roots far earlier in time than the expressed
pathophysiology (Gottesman and Hanson, 2005; Gross
et al., 2002; Koshibu et al., 2005; Weaver et al., 2004).
For many of the disorders that encompass mental ill-
ness or cognitive impairments, in which a complex
pathophysiology is reflected in microscopic and quanti-
tative, rather than macroscopic and qualitative, differ-
ences in brain development, we expect that an interac-
tion of polygenic vulnerability and environmental
influences underlies the disease etiology (Figure 1). For
example, while there are estimates of 15 or more genes
for autism (Veenstra-Vanderweele et al., 2004) and per-
haps up to 50 genes for schizophrenia (Lewis et al.,
2003; Shirts and Nimgaonkar, 2004) that may be in-
volved combinatorially in increasing vulnerability, many
different environmental insults have also been iden-
tified as increasing risk. Abbeduto and colleagues (Ab-
beduto et al., 2001) noted the particular conundrum
faced: “In the case of neurodevelopmental disorders, it
is important to recognize that the underlying genetic
pathology affects not only the behaviors and character-
istics that the individual ‘brings’ with him or her into the
world (i.e., the so-called direct effects of genes), but
also the environments in which the individual is embed-
ded, which in turn will influence his or her develop-*Correspondence: pat.levitt@vanderbilt.edument.” This makes perfect sense to developmental
neurobiologists, who have contributed to a detailed un-
derstanding of the role of genes and experience on
brain development, though generally by way of experi-
mental paradigms utilized in parallel, rather than to-
gether.
Is the developmental conundrum lost in the efforts to
translate basic research findings rapidly into a clearer
understanding of clinical disorders? For example, if the
initial wiring of the basic circuitry mediating hearing is
abnormal as a result of a genetic perturbation, the audi-
tory experiences that follow, which normally are re-
sponsible for the precision with which the sensory map
forms (Nakahara et al., 2004), will be interpreted in a
fundamentally different fashion than by circuitry that is
unperturbed by genetic insult. Thus, a decidedly dif-
ferent circuit, which has been influenced both by the
initial genetic perturbation and by incoming stimuli, has
been built and continues to drive the developmental
process on a trajectory distinct from that which it nor-
mally would have followed. This scenario is familiar to
those investigating the pathogenic process underlying
developmental epilepsy (Noebels, 2003; Swann, 2004),
where fundamental disturbances in the balance of exci-
tation and inhibition, perhaps caused by a gene muta-
tion encoding an ion channel or GABA receptor subunit
(Noebels, 2003), result in cortical circuitry with dis-
rupted activity, which, over time, may drive the more
apparent components of the pathogenic process. This
puzzle is arguably our greatest challenge in under-
standing the developmental etiology of complex mental
health and cognitive disorders. Our progress in meeting
this challenge depends upon mutual enlightenment by
developmental neurobiologists and clinicians, the latter
including physicians, psychologists, and educators.
Understandably, the research focus has been on the
developing cerebral cortex, as well as the structures
with which it interconnects to mediate complex infor-
mation processing and emotional regulation. Whereas
all of the minireviews in this issue focus on our current
understanding of specific histogenic features of corti-
cal development, this essay is meant to examine our
progress and future prospects in translational develop-
mental neuroscience.
What We Know—Inherited Mental Retardation
and Disruption of Cortical Histogenesis
Mental retardation, a heterogeneous collection of de-
velopmental disabilities, is relatively common, affecting
1%–3% of the population (Roeleveld et al., 1997). The
causes are many and may include environmental in-
sults, such as in utero infection or exposure to neuro-
toxins, perinatal complications, or early postnatal
trauma, as well as genetic etiologies, such as chromo-
somal disruption or single gene defects. It is logical that
our most detailed understanding of how basic distur-
bances in cortical development may lead to brain dys-
function is found among the less common disorders,
such as the mental retardation (MR) syndromes caused
by inherited single gene defects. Here, the disrupted
genes generally are involved in controlling dynamic de-
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Figure 1. Clinical Disorders and Neural Development
Differences between individuals in genetic vulnerability (red and o
blue circles) for a neurodevelopmental disorder confer, among i
other features, distinct responses to the environmental terrain, m
which together influence brain development. Gene-by-gene in- p
teractions directly influence developmental trajectory (colored
ilines), resulting in the expression of distinct phenotypes that are
icharacteristic of a particular disorder. Biological models (e.g., ge-
onetic mutants, in vitro systems, protein-protein interactions) and
descriptive pathophysiology (e.g., postmortem, genetics, imaging, o
behavioral/cognitive assessment) contribute to hypotheses regard- d
ing disease pathogenesis and to defining the phenotypes specific h
to a neurodevelopmental disorder. While evidence-based treat-
tments are rooted in large part on successes in impacting a particu-
dlar clinical phenotype (e.g., language, cognitive, social interven-
itions), prevention of neurodevelopmental disorders will come from
understanding the details of their origin (pathogenesis). t
2
gvelopmental processes at the cellular level. For the
f
larger group of disorders, one assumes that, in the ab-
t
sence of lethality, the various affected biochemical
n
paths converge on basic disruption of cortical organ-
g
ization that leads to disturbances in connectivity, w
though it is a fair criticism that we know the global im- (
pact, but few details, about the cellular neuropathology r
of many MR syndromes. In silico analysis (Inlow and n
Restifo, 2004) identified over 280 genes that have been o
designated as causing mental retardation. These range i
quite dramatically in putative function, from genes that d
cause disruption of basic metabolic processes to those c
encoding proteins involved in regulating key histogenic i
events. Examples of the latter include genes charac- 2
terized as responsible for regulating the dynamics of g
neuronal cell migration in the developing cortex, includ- r
ing Lis1, tuberin (TSC1), doublecortin (DCX), and reelin t
(RLN); disruption of any one of these genes can result n
in various forms of lissencephaly (Olson and Walsh, s
2002), which occurs in every 1 in 100,000 live births. m
Basic research has been effective recently in defining i
in great detail the regulatory mechanisms controlling d
cell motility in which these genes are involved. This has 1
permitted a bridge between those clinical syndromes d
where neuronal displacement and dyslamination are r
hallmarks and disrupted molecular mechanisms that d
may underlie each disorder. d
Autosomal and X-linked genetic MR syndromes also a
ainvolve genes regulating other aspects of dynamic cel-ular development (Antonarakis and Van Aelst, 1998).
or example, there has been remarkable progress in
he identification of the complex intracellular effectors
f the small GTPase family of proteins (Govek et al.,
005). Dozens of proteins that form parts of signaling
omplexes have been identified, and their regulation is
he continued focus of major research efforts. The Rho
amily, which includes RhoA, Rac, and cdc42, com-
rises the major intracellular cascades for transducing
eceptor signaling required for cytoskeletal reorganiza-
ion related to neurite initiation, cell motility, process
olarization, axon guidance, and spine and synapse
ormation (Govek et al., 2005). Genetic disruption of in-
ividual Rho family members, at critical nodes of sig-
aling, can result in profound MR, but the neuropatho-
ogical details of rare human syndromes are insufficient
o link a particular neurodevelopmental processes to a
linical domain.
The idea that MR also may arise from the disruption
f more general molecular effectors of multiple events
n cortical development is evident in a number of the
ost common disorders. Fragile X syndrome perhaps
rovides the best potential to demonstrate a basic-clin-
cal link. It is among the most common of monogenic
nherited MR syndromes and is caused by expansion
f CGG trinucleotide repeats in the noncoding 5# region
f the FMR1 gene encoding the Fragile X mental retar-
ation protein, which regulates the targeting of perhaps
undreds of different mRNA species and their transla-
ion (Darnell et al., 2004; Jin et al., 2004). In this disor-
er, there appears to be selective structural defects,
ncluding immature spines, disrupted synapse forma-
ion, and abnormal synaptic plasticity (Dolen and Bear,
005; Hessl et al., 2004; Hinton et al., 1991). The histo-
enic impact of the FMR1 gene mutation is more speci-
ically targeted to these latter developmental events
han one would have expected, given the ubiquitous
ature of the protein function. In contrast, Rett and An-
elman’s syndromes produce profound and relatively
idespread disruption of brain structure and function
Caballero and Hendrich, 2005; Guerrini et al., 2003),
egressive in nature, that ends up including a large
umber of cellular constituents. Rett is an X-linked dis-
rder caused by sporadic mutations of MECP2, encod-
ng methyl-CpG binding protein 2, which is likely to involve
isturbances in the modulation of gene transcription be-
ause of its role in binding methylated DNA and recruit-
ng other chromatin-modifying complexes (Zoghbi,
003). The onset of this regressive disorder occurs in
irls 6–18 months old who appear otherwise normal,
esulting in severe cognitive and motor impairments
hat include microcephaly and dysmorphic cortical
eurons, though more selective than expected (Arm-
trong et al., 1995), given the clinical phenotype. Angel-
an’s syndrome is caused by various maternally inher-
ted molecular defects of chromosome 15, including
eletion of the region encoding UBE3A (Jiang et al.,
999), a ubiquitin protein ligase 3 involved in protein
egradation (Jiang and Beaudet, 2004). The mutation
esults in a profound and widespread impact on cortical
evelopment. Autosomal and X-linked genetic MR syn-
romes thus provide opportunities for bridging remark-
bly detailed accounts of complex molecular pathways
nd these disorders. Because of a well-delineated con-
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model studies will continue to prove particularly effec-
tive. From a strictly development-centric perspective,
however, the challenge of linking basic histogenic pro-
cesses to specific clinical features may be quite dif-
ficult.
Advances in Clinical and Neurodevelopmental
Spheres—Poised for Translation
Animal models of single-gene defects that cause MR in
children do not generate a one-to-one correspondence
of known clinical defects, but this should not be a sur-
prise, given that the specific environments/experiences
that may impact on the expression of the gene defect
are unique to each species. Yet, in these model sys-
tems, the conserved nature of protein function is re-
flected in disrupted processes that are likely to play a
role in the disorder (Watase and Zoghbi, 2003). The
Fragile X model is an interesting example, because the
focus on abnormal synaptic plasticity (Bear et al., 2004;
Huber et al., 2002), as well as disturbances in the com-
plex process of synapse formation, leads to obvious
questions regarding the balance between molecular
(activity-independent) and neurophysiological regula-
tion of synapse formation. Recent neurodevelopmental
studies indicate that we can address such questions.
For example, a number of molecules, such as FGF22
(Umemori et al., 2004), neuroligins (Chubykin et al.,
2005; Sara et al., 2005), or thrombospondins (Christo-
pherson et al., 2005) control synapse number in an ac-
tivity-independent fashion, but so to does depolariza-
tion, demonstrated by Murthy and colleagues in vitro
(Burrone et al., 2002). These basic findings could be
linked to produce a more detailed view of how disrup-
tion of synaptic development and function in humans,
such as occurs in Fragile X syndrome, leads to behav-
ioral and neuropathological phenotypes.
In order that a rational link to the disruption of basic
neurodevelopmental processes can be made, transla-
tion depends, to a large extent, on detailed information
of clinical disorders. There is an inherent weakness in
this dependence, however, because the technical rep-
ertoire that is brought to bear on analyzing clinical dis-
orders is far less impressive than in model systems in
the molecular and structural arenas. In contrast, we are
far more sophisticated in assessing cognitive and be-
havioral phenotypes in humans than we are in our bio-
logical models. For example, because of analysis in an-
imal model systems, the current understanding of
cortical development has advanced to general accep-
tance of the protomap hypothesis proposed by Rakic
decades ago (Rakic, 1978; Rakic, 1988), in which there
is sufficient genetic information in the cortex to specify
the unique regional properties of progenitor cells and
early neurons. The extent to which signaling centers
and transcription factors intrinsic to the dorsal pallium,
rather than thalamocortical axons, participate in the
specification process is now clear (Grove and Fukuchi-
Shimogori, 2003). Many of the molecules responsible
for mediating the guidance of axons to their appropri-
ate cortical areas and laminae have also been iden-
tified, including Eph receptors and ephrins, semapho-
rins and netrins, Ig superfamily members and integrins
(see Polleux, 2005, in this issue). It is just a matter of
time before a clear repertoire of molecules are charac-terized as essential for establishing the framework of
cortical afferent and efferent circuit organization,
though we remain relatively elementary in distinguish-
ing between those critical for inter- and intra-areal to-
pography. A recent report of a rare mutation of a G pro-
tein-coupled receptor that causes regionally selective
pachygyria (Piao et al., 2004) indicates that indeed
many of the mechanisms of cortical specification
shown in rodents are likely invoked for human cortical
development. Other than this example, however, the
degree to which the efforts in understanding cortical
specification and basic wiring in rodents have been
translated to relatively common human disorders, such
as autism spectrum (1 in 166) or schizophrenia (1 in
100), has been minimal. Perhaps it is not ready for
“prime time,” in part due to the lack of replicated au-
tism susceptibility genes (Belmonte et al., 2004;
Spence, 2004) and only a handful of replicable findings
in schizophrenia (Harrison and Weinberger, 2005; Shirts
and Nimgaonkar, 2004). Alternatively, the develop-
mental etiology simply may not include fundamental
problems in cortical regionalization and basic activity-
independent wiring. What is the evidence?
Autism has, as its core features, impairments of so-
cial interaction, difficulties in communication, and a
repertoire of repetitive behaviors and restricted inter-
ests. Complicating the classic DSM-IV criteria for diag-
nosis, autism is a spectrum disorder for which each of
the three core features may be more or less impaired
(Minshew et al., 1997). Additionally, there are certain
multisensory defects, selective dominance of visuo-
spatial functions, high incidence of subthreshold EEG
abnormalies, and comorbidities with sleep-wake cycle
anomalies (w25%), frank epilepsy (w15%–25%), and
MR (w50%) (Malow, 2004; Minshew et al., 1997;
Spence et al., 2004; Tuchman, 2003). Anxiety, joint at-
tention, and novelty-seeking are also behavioral do-
mains disrupted in autism (Belmonte et al., 2004). Be-
yond the central disturbances, there is a relatively high
incidence of medical problems that can include gastro-
intestinal disorders and allergies (Ashwood and Van de
Water, 2004; Chez et al., 2004; Spence et al., 2004),
suggesting that genes with shared importance in the
development of brain and certain peripheral organs
may be involved. From a developmental perspective,
the unique phenotypes of autism intersect with the
possibility that there are ontogenetic disturbances in
two highly conserved features of cortical organization
(Casanova et al., 2002; Levitt et al., 2004), the balance
of excitation:inhibition (Levitt et al., 2004; Rubenstein
and Merzenich, 2003) and the organization of the fun-
damental information processing unit, the cortical mini-
column (Mountcastle, 1997), both of which require ap-
propriate interneuron organization function. Rapid
progress in understanding interneuron development
was marked by the seminal findings of de Carlos et al.
(de Carlos et al., 1996) and Anderson and Rubenstein
(Anderson et al., 1997) regarding the predominant sub-
pallial origin of interneurons, continuing with studies
demonstrating that altered interneuron number can be
compatible with long-term survival and can manifest as
regional and subtype-specific defects that cause be-
havioral phenotypes (Powell et al., 2003; Powell et al.,
2001). Recent studies also provide evidence of a potent
Neuron
410role for GABA neurotransmission in dictating the
(precision with which sensory maps form (Fagiolini et
al., 2004; Hensch and Stryker, 2004), which could relate w
ito both the multisensory disturbances and hyperacuity
in the visuospatial domain in autism. We can add to the s
spoints of convergence the latest reports of neuron-glial
interactions that involve interneuron modulation of oli- o
2godendrocyte precursors (Lin and Bergles, 2004a; Lin
and Bergles, 2004b). There have been a number of k
lmolecules identified as actively guiding interneuron mi-
gration (see Flames and Marín, 2005, this issue), but i
dputative targets of gene mutations and environmental
triggers may be just as likely to involve the disruption n
uof mechanisms responsible for generating interneuron
diversity (morphology, neurochemistry, intrinsic physio- t
dlogical properties) (Monyer and Markram, 2004) or cell-
cell interactions. a
iIt is unlikely that a disorder as complex as autism can
be explained by an alteration of one principle cellular i
acomponent. Long axon pathways, and even perhaps
myelination itself, are disrupted in autism, though there a
sis insufficient detail to understand the selective nature
of possible altered connectivity. For example, recent L
eprospective structural imaging studies of children with
autism, as well as retrospective clinical data, indicate m
fthat there is a highly unusual pattern of growth for spe-
cific brain structures. Children with autism tend to fall z
2into the highest quartile ranking of head circumference,
and there is a reported increase in the size of certain t
gwhite matter pathways in the frontal and temporal re-
gions of the cerebral hemispheres (Courchesne, 2004; t
nCourchesne et al., 2003; Herbert et al., 2004). Consis-
tent with the findings, the amygdala and hippocampus (
Lexhibit highly unusual patterns of overgrowth in chil-
dren with autism (Schumann et al., 2004). The lack of t
winformation regarding a cellular basis for these repli-
cated findings of disturbed gray and white matter b
wmakes the phenomena difficult to understand in a de-
velopmental context. Yet, our rapid understanding of d
cthe control of dendritic growth in this brain area forms
an intriguing bridge to the altered growth trajectory of D
ecortical gray matter. The mechanisms of activity-inde-
pendent and -dependent dendrite maturation that have p
wbeen elucidated in exquisite detail (see Konur and
Ghosh, 2005, this issue) could also relate to altered wir- e
ming in autism. For example, pleiotropic molecules, such
as semaphorin 3A, slit1, and BDNF (which has been T
cimplicated in autism; Miyazaki et al., 2004; Nelson et
al., 2001) influence the initial phases of apical and basal p
rdendritic outgrowth differentially (McAllister, 2002; Pol-
leux et al., 2000; Whitford et al., 2002a; Whitford et al., a
f2002b). Genetic vulnerability thus might establish dis-
rupted dendritic growth regulation, which may then be T
mexacerbated by abnormal, Ca2+-dependent activity pat-
terns that influence the ultimate extent of dendritic a
sgrowth, branching, and spine formation (Dijkhuizen and
Ghosh, 2005). I am suggesting that examination of how F
Ca genetic disruption, which causes selective dendritic
overgrowth, combines with an environmental perturba- t
rtion, such as early infection (Shi et al., 2003), to produce
altered circuitry, can provide as much or more insight a
has studying an animal model exhibiting the character-
istic overgrowth features reported in children with M
dautism.Schizophrenia, as a neurodevelopmental disorder
Lewis and Levitt, 2002; Weinberger, 1987), in some
ays poses a greater puzzle because of the etiology
n which there is a postpubertal onset of psychiatric
ymptoms. There are, however, several developmental
tudies that have modeled a postpubertal, temporal eti-
logy (Gross et al., 2002; Koshibu et al., 2005; Lipska,
004). Moreover, in contrast to autism, in which little is
nown regarding a cortical phenotype at the cellular
evel, quantitative studies of the cerebral cortex from
ndividuals with schizophrenia relate a highly selective
isruption of neuropil elements and subpopulations of
eurons. Thus, we are poised to translate our detailed
nderstanding of the regulation of histogenic events to
he underlying pathogenesis of the disorder. The neuro-
evelopmental events that are the focus of this volume
re not likely to be disrupted, however, because there
s no reproducible evidence of disturbances that would
nvolve abnormal cell genesis, migration, or axon guid-
nce. Rather, the neuropil and cellular changes (Lewis
nd Lieberman, 2000), such as reduced synaptic den-
ity (Selemon, 2001), basal dendritic spines (Glantz and
ewis, 2000), and certain interneuron subtypes (Lewis
t al., 2005), invoke a number of later-onset develop-
ental events. These data suggest that there may be
laws in wiring that relate to synapse formation, stabili-
ation, or elimination (for example, see Manji et al.,
003; Mirnics et al., 2001), which occur over a pro-
racted period in humans (Bourgeois, 1997). There are
enetic and experimental data that are consistent with
he involvement of altered maturation of a number of
eurotransmitter systems, including cortical glutamate
Moghaddam, 2003) and GABA (Levitt et al., 2004;
ewis et al., 2005). We also know from monozygotic
win studies, in which schizophrenia concordance is
45%, that the neurodevelopmental disruption must
e due to a complex genetic vulnerability combined
ith environmentally induced disturbances. Although
ebates regarding the former are unsettled, gene asso-
iation findings for neuregulin, dysbindin, RGS4, and
ISC1, as well as gene expression studies (Middleton
t al., 2002; Mirnics et al., 2000; Vawter et al., 2001),
oint toward synaptic disturbances that are consistent
ith the cortical neuropathology in schizophrenia. An
xperimental bridge to study the underlying develop-
ental mechanisms of schizophrenia now is available.
his might involve an examination of (1) molecules that
an modulate synapse formation in an activity-inde-
endent fashion, (2) existing genetic models that dis-
upt, developmentally, properties of synaptic function,
nd (3) environmental perturbations that are known
rom epidemiological studies to increase disease risk.
hus, we now have the necessary tools to define, far
ore precisely, the interaction of activity-independent
nd -dependent variables that would lead to a disorder
uch as schizophrenia.
inding Translation
linical heterogeneity is often overlooked as an impor-
ant feature that links basic and clinical studies on neu-
odevelopmental disorders. While there may not be an
bsolute continuum, there is no doubt that disease
eterogeneity, in terms of cause and effect, exists.
oreover, endophenotypes, those marker traits of a
isorder that may be expressed by nonaffected family
Minireview
411members, also reflect the complex and heterogeneous
nature of clinical disorders. This is entirely consistent
with our current state of knowledge regarding funda-
mental mechanisms governing cortical development. In
fact, we know that, in large part, there is a rather selec-
tive nature to both genetic and environmental disrup-
tion. Cell context (i.e., receptor heterogeneity) is an
essential element of stem and progenitor cell behavior;
projection and interneurons have very different require-
ments for establishing their appropriate numerical and
phenotypic properties; the molecules and physiological
activities responsible for wiring are highly complex and
clearly impact distinct cortical populations differently. I
stated at the outset that neural development is a pris-
oner of a most extraordinary gene-environment “catch-
22.” In a sense, then, clinical phenotypes provide a data
set of biological titrations and thus serve as the link to
basic research strategies that can now move to being
more combinatorial in nature in order to be truly transla-
tional.
Acknowledgments
I am grateful to Dr. Kathie Eagleson for comments and suggestions
regarding this review. Supported in part by Vanderbilt Kennedy
Center NICHD Core Grant P30 HD15052.
Selected Reading
Abbeduto, L., Evans, J., and Dolan, T. (2001). Ment. Retard. Dev.
Disabil. Res. Rev. 7, 45–55.
Anderson, S.A., Eisenstat, D.D., Shi, L., and Rubenstein, J.L. (1997).
Science 278, 474–476.
Antonarakis, S.E., and Van Aelst, L. (1998). Nat. Genet. 19, 106–108.
Armstrong, D., Dunn, J.K., Antalffy, B., and Trivedi, R. (1995). J.
Neuropathol. Exp. Neurol. 54, 195–201.
Ashwood, P., and Van de Water, J. (2004). Clin. Dev. Immunol. 11,
165–174.
Bear, M.F., Huber, K.M., and Warren, S.T. (2004). Trends Neurosci.
27, 370–377.
Belmonte, M.K., Cook, E.H., Jr., Anderson, G.M., Rubenstein, J.L.,
Greenough, W.T., Beckel-Mitchener, A., Courchesne, E., Boulanger,
L.M., Powell, S.B., Levitt, P.R., et al. (2004). Mol. Psychiatry 9,
646–663.
Bourgeois, J.P. (1997). Acta Paediatr. Suppl. 422, 27–33.
Burrone, J., O'Byrne, M., and Murthy, V.N. (2002). Nature 420,
414–418.
Caballero, I.M., and Hendrich, B. (2005). Hum. Mol. Genet. 14,
R19–R26.
Casanova, M.F., Buxhoeveden, D.P., Switala, A.E., and Roy, E.
(2002). Neurology 58, 428–432.
Chez, M.G., Memon, S., and Hung, P.C. (2004). Semin. Pediatr. Neu-
rol. 11, 229–235.
Christopherson, K.S., Ullian, E.M., Stokes, C.C., Mullowney, C.E.,
Hell, J.W., Agah, A., Lawler, J., Mosher, D.F., Bornstein, P., and Bar-
res, B.A. (2005). Cell 120, 421–433.
Chubykin, A.A., Liu, X., Comoletti, D., Tsigelny, I., Taylor, P., and
Sudhof, T.C. (2005). J. Biol. Chem., in press
Courchesne, E. (2004). Ment. Retard. Dev. Disabil. Res. Rev. 10,
106–111.
Courchesne, E., Carper, R., and Akshoomoff, N. (2003). JAMA 290,
337–344.
Darnell, J.C., Warren, S.T., and Darnell, R.B. (2004). Ment. Retard.
Dev. Disabil. Res. Rev. 10, 49–52.de Carlos, J.A., Lopez-Mascaraque, L., and Valverde, F. (1996). J.
Neurosci. 16, 6146–6156.
Dijkhuizen, P.A., and Ghosh, A. (2005). Prog. Brain Res. 147, 17–27.
Dolen, G., and Bear, M.F. (2005). Neuron 45, 642–644.
Fagiolini, M., Fritschy, J.M., Low, K., Mohler, H., Rudolph, U., and
Hensch, T.K. (2004). Science 303, 1681–1683.
Flames, N., and Marín, O. (2005). Neuron 46, this issue, 377–381.
Glantz, L.A., and Lewis, D.A. (2000). Arch. Gen. Psychiatry 57, 65–
73.
Gottesman, I.I., and Hanson, D.R. (2005). Annu. Rev. Psychol. 56,
263–286.
Govek, E.E., Newey, S.E., and Van Aelst, L. (2005). Genes Dev. 19,
1–49.
Gross, C., Zhuang, X., Stark, K., Ramboz, S., Oosting, R., Kirby, L.,
Santarelli, L., Beck, S., and Hen, R. (2002). Nature 416, 396–400.
Grove, E.A., and Fukuchi-Shimogori, T. (2003). Annu. Rev. Neurosci.
26, 355–380.
Guerrini, R., Carrozzo, R., Rinaldi, R., and Bonanni, P. (2003). Paedi-
atr. Drugs 5, 647–661.
Harrison, P.J., and Weinberger, D.R. (2005). Mol. Psychiatry 10, 420.
Hensch, T.K., and Stryker, M.P. (2004). Science 303, 1678–1681.
Herbert, M.R., Ziegler, D.A., Makris, N., Filipek, P.A., Kemper, T.L.,
Normandin, J.J., Sanders, H.A., Kennedy, D.N., and Caviness, V.S.,
Jr. (2004). Ann. Neurol. 55, 530–540.
Hessl, D., Rivera, S.M., and Reiss, A.L. (2004). Ment. Retard. Dev.
Disabil. Res. Rev. 10, 17–24.
Hinton, V.J., Brown, W.T., Wisniewski, K., and Rudelli, R.D. (1991).
Am. J. Med. Genet. 41, 289–294.
Huber, K.M., Gallagher, S.M., Warren, S.T., and Bear, M.F. (2002).
Proc. Natl. Acad. Sci. USA 99, 7746–7750.
Inlow, J.K., and Restifo, L.L. (2004). Genetics 166, 835–881.
Jiang, Y.H., and Beaudet, A.L. (2004). Curr. Opin. Pediatr. 16, 419–
426.
Jiang, Y., Lev-Lehman, E., Bressler, J., Tsai, T.F., and Beaudet, A.L.
(1999). Am. J. Hum. Genet. 65, 1–6.
Jin, P., Alisch, R.S., and Warren, S.T. (2004). Nat. Cell Biol. 6,
1048–1053.
Konur, S., and Ghosh, A. (2005). Neuron 46, 000–000.
Koshibu, K., Ahrens, E.T., and Levitt, P. (2005). J. Neurosci. 25,
3870–3880.
Levitt, P., Eagleson, K.L., and Powell, E.M. (2004). Trends Neurosci.
27, 400–406.
Lewis, D.A., and Levitt, P. (2002). Annu. Rev. Neurosci. 25, 409–432.
Lewis, D.A., and Lieberman, J.A. (2000). Neuron 28, 325–334.
Lewis, C.M., Levison, D.F., Wise, L.H., DeLisi, L.E., Straub, R.E.,
Hovatta, I., Williams, N.M., Schwab, S.G., Pulver, A.E., Faraone,
S.V., et al. (2003). Am. J. Hum. Genet. 73, 34–48.
Lewis, D.A., Hashimoto, T., and Volk, D.W. (2005). Nat. Rev. Neu-
rosci. 6, 312–324.
Lin, S.C., and Bergles, D.E. (2004a). Nat. Neurosci. 7, 24–32.
Lin, S.C., and Bergles, D.E. (2004b). Glia 47, 290–298.
Lipska, B.K. (2004). J. Psychiatry Neurosci. 29, 282–286.
Malow, B.A. (2004). Ment. Retard. Dev. Disabil. Res. Rev. 10, 122–
125.
Manji, H.K., Gottesman, I.I., and Gould, T.D. (2003). Sci. STKE, 49.
McAllister, A.K. (2002). Neuron 33, 2–4.
Middleton, F.A., Mirnics, K., Pierri, J.N., Lewis, D.A., and Levitt, P.
(2002). J. Neurosci. 22, 2718–2729.
Minshew, N.J., Goldstein, G., and Siegel, D.J. (1997). J. Int. Neuro-
psychol. Soc. 3, 303–316.
Mirnics, K., Middleton, F.A., Marquez, A., Lewis, D.A., and Levitt, P.
(2000). Neuron 28, 53–67.
Mirnics, K., Middleton, F.A., Lewis, D.A., and Levitt, P. (2001).
Trends Neurosci. 24, 479–486.
Neuron
412Miyazaki, K., Narita, N., Sakuta, R., Miyahara, T., Naruse, H., Okado,
N., and Narita, M. (2004). Brain Dev. 26, 292–295.
Moghaddam, B. (2003). Neuron 40, 881–884.
Monyer, H., and Markram, H. (2004). Trends Neurosci. 27, 90–97.
Mountcastle, V.B. (1997). Brain 120, 701–722.
Nakahara, H., Zhang, L.I., and Merzenich, M.M. (2004). Proc. Natl.
Acad. Sci. USA 101, 7170–7174.
Nelson, K.B., Grether, J.K., Croen, L.A., Dambrosia, J.M., Dickens,
B.F., Jelliffe, L.L., Hansen, R.L., and Phillips, T.M. (2001). Ann. Neu-
rol. 49, 597–606.
Noebels, J.L. (2003). Annu. Rev. Neurosci. 26, 599–625.
Olson, E.C., and Walsh, C.A. (2002). Curr. Opin. Genet. Dev. 12,
320–327.
Piao, X., Hill, R.S., Bodell, A., Chang, B.S., Basel-Vanagaite, L.,
Straussberg, R., Dobyns, W.B., Qasrawi, B., Winter, R.M., Innes,
A.M., et al. (2004). Science 303, 2033–2036.
Polleux, F. (2005). Neuron 46, this issue, 395–400.
Polleux, F., Morrow, T., and Ghosh, A. (2000). Nature 404, 567–573.
Powell, E.M., Mars, W.M., and Levitt, P. (2001). Neuron 30, 79–89.
Powell, E.M., Campbell, D.B., Stanwood, G.D., Davis, C., Noebels,
J.L., and Levitt, P. (2003). J. Neurosci. 23, 622–631.
Rakic, P. (1978). Postgrad. Med. J. 54, 25–40.
Rakic, P. (1988). Science 241, 170–176.
Roeleveld, N., Zielhuis, G.A., and Gabreels, F. (1997). Dev. Med.
Child Neurol. 39, 125–132.
Rubenstein, J.L., and Merzenich, M.M. (2003). Genes Brain Behav.
2, 255–267.
Sara, Y., Biederer, T., Atasoy, D., Chubykin, A., Mozhayeva, M.G.,
Sudhof, T.C., and Kavalali, E.T. (2005). J. Neurosci. 25, 260–270.
Schumann, C.M., Hamstra, J., Goodlin-Jones, B.L., Lotspeich, L.J.,
Kwon, H., Buonocore, M.H., Lammers, C.R., Reiss, A.L., and
Amaral, D.G. (2004). J. Neurosci. 24, 6392–6401.
Selemon, L.D. (2001). Schizophr. Bull. 27, 349–377.
Shi, L., Fatemi, S.H., Sidwell, R.W., and Patterson, P.H. (2003). J.
Neurosci. 23, 297–302.
Shirts, B.H., and Nimgaonkar, V. (2004). Curr. Psychiatry Rep. 6,
303–312.
Spence, S.J. (2004). Semin. Pediatr. Neurol. 11, 196–204.
Spence, S.J., Sharifi, P., and Wiznitzer, M. (2004). Semin. Pediatr.
Neurol. 11, 186–195.
Swann, J.W. (2004). Ment. Retard. Dev. Disabil. Res. Rev. 10, 96–
100.
Tuchman, R. (2003). Neurol. Clin. 21, 915–932.
Umemori, H., Linhoff, M.W., Ornitz, D.M., and Sanes, J.R. (2004).
Cell 118, 257–270.
Vawter, M.P., Barrett, T., Cheadle, C., Sokolov, B.P., Wood, W.H.,
3rd, Donovan, D.M., Webster, M., Freed, W.J., and Becker, K.G.
(2001). Brain Res. Bull. 55, 641–650.
Veenstra-Vanderweele, J., Christian, S.L., and Cook, E.H., Jr. (2004).
Annu. Rev. Genomics Hum. Genet. 5, 379–405.
Watase, K., and Zoghbi, H.Y. (2003). Nat. Rev. Genet. 4, 296–307.
Weaver, I.C., Cervoni, N., Champagne, F.A., D'Alessio, A.C.,
Sharma, S., Seckl, J.R., Dymov, S., Szyf, M., and Meaney, M.J.
(2004). Nat. Neurosci. 7, 847–854.
Weinberger, D.R. (1987). Arch. Gen. Psychiatry 44, 660–669.
Whitford, K.L., Dijkhuizen, P., Polleux, F., and Ghosh, A. (2002a).
Annu. Rev. Neurosci. 25, 127–149.
Whitford, K.L., Marillat, V., Stein, E., Goodman, C.S., Tessier-
Lavigne, M., Chedotal, A., and Ghosh, A. (2002b). Neuron 33, 47–61.
Zoghbi, H.Y. (2003). Science 302, 826–830.
